Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Rybelsus Cognitive Function Impact: What the Evidence Actually Shows

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Approved uses / blood sugar control in type 2 diabetes; cardiovascular risk reduction in high-risk type 2 diabetes [1]
  • Cognitive or dementia indication / none listed on the label [1]
  • Human data cited here / liraglutide, 26 weeks, 38 Alzheimer's patients; cognitive scores unchanged [2]
  • Oral semaglutide outcome trial / SOUL measured cardiovascular events (12.0% vs 13.8% over a median 49.5 months), not cognition [3]

Does Rybelsus affect memory or thinking?

Rybelsus is oral semaglutide, a GLP-1 receptor agonist. Its label lists two uses: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them [1]. Neither use involves memory, thinking or dementia.

A small liraglutide trial in Alzheimer's disease, not a Rybelsus trial

A 26-week randomized, double-blind, placebo-controlled trial gave injectable liraglutide to 18 patients with Alzheimer's disease and placebo to 20 [2]. FDG-PET showed brain glucose metabolism declining in the placebo group in the precuneus, the parietal, temporal and occipital lobes, and the cerebellum. The liraglutide group showed a numerical but non-significant increase [2]. Cognitive scores did not change, and the authors noted the study was underpowered for its amyloid and cognition measures [2].

In mice, exendin-4, another GLP-1 receptor agonist, given after an experimental stroke reduced stroke volume and neuron loss [4]. That is animal data from a different drug.

Heart results are not cognitive results

SOUL randomized 9,650 adults aged 50 or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, to oral semaglutide up to 14 mg daily or placebo. Cardiovascular death, non-fatal myocardial infarction or non-fatal stroke occurred in 12.0% versus 13.8% over a median 49.5 months (hazard ratio 0.86) [3]. The primary outcome was cardiovascular events, not cognitive scores [3].

Frequently asked questions

Does Rybelsus improve memory or treat Alzheimer's disease?
No such use is approved, and memory benefit has not been shown. The label lists glycemic control and cardiovascular risk reduction in type 2 diabetes [1]. In a small trial of a different GLP-1 drug, liraglutide did not change cognitive scores over 26 weeks in 38 people with Alzheimer's disease [2].
How does semaglutide act in the brain?
Semaglutide selectively binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake.

References

  1. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  2. Gejl M, Gjedde A, Egefjord L, Møller A, Hansen SB, Vang K, et al. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci. 2016;8:108. In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
  3. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
  4. Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nyström T, et al. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PLoS One. 2014;9(8):e103114. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization
Evidence overview for Rybelsus Cognitive Function Impact: What the Evidence Actually Shows